Risk for second bladder and rectal malignancies from cervical cancer irradiation

Michalis Mazonakis\(^1\)  |  Efrosyni Lyraraki\(^2\)  |  Maria Tolia\(^2\)  |  John Damilakis\(^1\)

\(^1\)Department of Medical Physics, Faculty of Medicine, University of Crete, Crete, Greece
\(^2\)Department of Radiotherapy and Oncology, University Hospital of Iraklion, Iraklion, Crete, Greece

Author to whom correspondence should be addressed. Michalis Mazonakis
E-mail: mazonak@uoc.gr

Abstract

The objective of this study was to estimate the risk of developing second malignancies to partially in-field organs from volumetric modulated arc therapy (VMAT) of cervical cancer and to compare the above risks with those from the conventional three-dimensional conformal radiotherapy (3D-CRT). Seventeen consecutive patients with uterine cervix carcinoma were selected. VMAT and 3D-CRT plans were generated with 6 and 10 MV photons, respectively. The prescribed tumor dose was 45 Gy given in 25 fractions. Differential dose-volume histogram data from the treatment plans were obtained for the partially in-field organs such as bladder and rectum. These data were used to estimate the patient-specific lifetime attributable risk (LAR) for bladder and rectal cancer induction with a non-linear model based on a mixture of plateau and bell-shaped dose–response relationships. The estimated risks per 10000 people were compared with the baseline risks for unexposed population. The patient-specific rectal cancer risk estimates from VMAT were significantly lower than those from 3D-CRT (\(P = 0.0144\)). The LARs for developing bladder malignancies from VMAT were significantly high compared to those from conventional irradiation (\(P = 0.0003\)). The mean difference between the patient-specific LARs for radiation-induced bladder and rectal malignancies as derived from 3D-CRT and VMAT plans was 6.6% and 2.0%, respectively. The average LAR for developing bladder and rectal malignant diseases due to VMAT was \(9.2 \times 10^{-4}\) and \(43.7 \times 10^{-4}\), respectively. The corresponding risks following 3D-CRT were \(8.6 \times 10^{-4}\) and \(44.6 \times 10^{-4}\). These average risks showed that pelvic irradiation increases the baseline probability for cancer induction by 12.6-19.1%. The differences in the second cancer risks associated with the VMAT and 3D-CRT for cervical cancer were found to be small. Both treatment techniques resulted in considerable increased probabilities for developing bladder and rectal malignancies relative to those of unirradiated population.

KEY WORDS

3D-CRT, cervical cancer, second malignancies, VMAT
1 | INTRODUCTION

Cervical cancer is the fourth most frequent malignant disease and, also, the fourth main cause of cancer mortality in females globally. The 5-year survival rate of this type of cancer is 66.1% and it reaches to 91.8% for localized disease stage. Radiation therapy plays a major role in the management of the uterine cervix carcinoma. Previous studies reported that the therapeutic irradiation of this gynecological cancer is associated with an increased probability for developing second malignancies to surrounding heavily exposed sites such as urinary bladder and rectum. The above results were derived from patients irradiated before 2001 without advanced treatment delivery and planning approaches.

The VMAT for cervical cancer has gained popularity the last decade due to the decrease of the treatment delivery time and monitor unit (MU) usage in comparison with IMRT. No attempts have been made to assess the probability for second cancer development in patients subjected to VMAT for gynecological carcinomas. This study was conducted to estimate the risks for developing second malignancies to critical partially in-field organs such as bladder and rectum following VMAT for cervical cancer. They found that IMRT results in a higher cumulative cancer risk than 3D-CRT.

The VMAT for cervical cancer has gained popularity the last decade due to the decrease of the treatment delivery time and monitor unit (MU) usage in comparison with IMRT. No attempts have been made to assess the probability for second cancer development in patients subjected to VMAT for gynecological carcinomas. This study was conducted to estimate the risks for developing second malignancies to critical partially in-field organs such as bladder and rectum following VMAT for cervical cancer and to compare the aforementioned risks with those resulting from conventional 3D-CRT.

2 | MATERIALS AND METHODS

2.A | CT scanning and contouring

Seventeen consecutive patients with localized carcinoma of the uterine cervix were included in this work. The patient’s age ranged from 40 to 68 yrs old with a mean age of 53.1 ± 9.2 yrs (Fig. 1). The study participants underwent a planning computed tomography (CT) examination in supine treatment position. The CT slice thickness was 5 mm without a gap. All CT datasets were transferred to Monaco system (Elekta AB, Stockholm, Sweden) for contouring and planning. The RTOG-0418 guidelines were used to define the targets and organs at risk (OARs) on the CT scans acquired with a full urinary bladder and an empty rectum. The clinical target volume (CTV) comprised the upper 3.0 cm of vagina and paravaginal soft tissue lateral to the vagina. The internal, external and common iliac lymph nodes, and presacral nodal regions were also included within the CTV. A 7-mm margin was applied to uniformly expand the CTV to the planning target volume (PTV). The bowel, rectum, urinary bladder, and femoral heads were manually delineated on the CT scans as the organs-at-risk (OARs). The study protocol was approved by the ethics committee of our institution. A written informed consent was obtained by the participants.

2.B | 3D-CRT and VMAT planning

For each patient, treatment plans were generated with 3D-CRT and VMAT for delivery on a medical linear accelerator (Infinity, Elekta AB, Stockholm, Sweden) emitting 6 and 10 MV photons. The PTV prescribed dose was 45 Gy given in 25 daily fractions of 1.8 Gy. The 3D-CRT plans involved 10 MV photon beams. The beam arrangement consisted of an anteroposterior, a posteroanterior and two lateral opposed treatment fields at the following gantry angles: of 0°, 90°, 120°, and 270°. The beam weight was optimized for each separate plan in order to achieve a homogeneous dose distribution within the PTV and reduce the radiation dose to surrounding structures. The planning aim was to cover at least 95% of the PTV with the 95% of the prescribed dose.

The VMAT plans were created with 6 MV photons. Two coplanar full arcs rotating in clockwise and anticlockwise directions were used. The segment width was set to 1.0 cm and the increment of gantry was 30°. All VMAT plans were designed to satisfy the dose constraints introduced by the RTOG 0418 for modulated radiotherapy. These constraints are summarized in Table 1. Furthermore, the maximum PTV dose was kept below 49.5 Gy whereas less than 1% of the target volume received a dose smaller than 93% of the prescribed dose. No more than 1% or 1 cm³ (whichever is lower) of the healthy tissues outside PTV absorbed a radiation dose exceeding 110% of the tumor dose.
Table 1 Dosimetric constraints of the planning target volume (PTV) and surrounding critical organs applied for VMAT planning.

| Structure          | \( V_i \)  |
|--------------------|-------------|
| PTV                | \( V_{45} \geq 97\% \) |
| Bowel              | \( V_{40} < 30\% \) |
| Rectum             | \( V_{30} < 60\% \) |
| Bladder            | \( V_{45} < 35\% \) |
| Femoral heads      | \( V_{30} \leq 15\% \) |

*The \( V_i \) corresponds to the structure volume absorbing a radiation dose of \( i \) Gy.

2.C Estimation of the patient-specific cancer risk

Pelvic radiation therapy for gynecological carcinomas may result in second bladder and rectal malignant diseases. The above structures were characterized as partially in-field organs in accordance with a previous study of Howell et al. The above OARs were adjacent to the target volume and they received an inhomogeneous dose distribution in the 3D-CRT and VMAT plans of all study participants. Parts of both rectum and urinary bladder absorbed radiation doses up to that of the PTV.

Hall reported that the risk of radiation carcinogenesis is linearly related to the absorbed dose for a range of 0.1–2.5 Gy. Dasu and Toma-Dasu also stated that the linear relationship exists up to doses of 1–2 Gy. The extrapolation of the linear-no-threshold approach to doses exceeding the above levels is not recommended. There are several non-linear models in the literature which ignore either the fractionation or the cell proliferation effects occurring during radiotherapy. Schneider et al. introduced a mechanistic model providing site-specific dose response relations using data obtained by A-bomb survivors and irradiated Hodgkin’s disease patients. This mechanistic model is based on a mixture of plateau and bell-shaped dose response relationships. The model-based cancer risk estimates account for the tumor dose fractionation and the interfraction repair of the exposed tissues.

The above non-linear mechanistic model was applied to estimate the cancer risk to bladder and rectum from radiation therapy for cervical cancer. The probability of carcinogenesis to critical organs has been previously assessed with this model for patients irradiated for carcinomas and benign disorders. The application of the mechanistic model required the knowledge of the organ equivalent dose (OED) of each OAR. Differential dose-volume histograms were used to calculate the OED of the bladder or rectum from the 3D-CRT and VMAT plans of each patient as follows:

\[
OED = \frac{1}{V_T} \sum V_{D_i} e^{-a_i D_i} \left[ 1 - 2R + R^2 e^{-a_i D_i} - (1 - R) e^{-a_i D_i} \right] \tag{1}
\]

where \( V_T \) is the total organ volume, \( V_{D_i} \) is the organ volume receiving a dose equal to \( D_i \), \( R \) is a factor associated with the organ-dependent repopulation and \( a_i \) is the cell killing factor. The \( a_i \) was calculated using the formula:

\[
a_i' = a + \beta D_i \frac{D_i}{D_i^*} \tag{2}
\]

where \( a \) and \( \beta \) are the linear quadratic parameters, \( D_i \) is the PTV dose of 1.8 Gy delivered in each fraction and \( D_i^* \) is the total target dose of 45 Gy.

The patient-dependent excess absolute risk (EAR) for the appearance of radiation-induced bladder or rectal malignancies due to 3D-CRT or VMAT for cervical cancer was estimated as follows:

\[
EAR = OED_{\beta_{EAR}} \exp \left[ \gamma_{e} (age_e - 30) + \gamma_{a} \ln \left( \frac{age_e}{70} \right) \right] \tag{3}
\]

where \( \beta_{EAR} \) is the initial slope at low doses of the dose-response curve for a Western population, \( \gamma_e \) and \( \gamma_{a} \) are the age modifying parameters for each organ of interest, \( age_e \) is the age of the female patient during radiation therapy and \( age_a \) is the attained age. The lifetime attributable risk (LAR) for second cancer induction was estimated with the formula:

\[
LAR = \int_{age_e - L}^{age_{e, max}} EAR(age_e, age_a) \frac{S(age_e)}{S(age_a)} d(age_a) \tag{4}
\]

where \( age_{e, max} \) was taken equal to 80 years, \( L \) is a cancer-risk free period of 5 years for the development of radiation-induced solid tumors and \( S(age_a) / S(age_e) \) is the probability of a healthy female to survive from \( age_e \) to \( age_a \) obtained by the United States life tables.

The parameters, \( R, a, \gamma_e, \gamma_{a, max} \) and \( \beta_{EAR} \) for the bladder were taken from the literature and they were 0.06, 0.219 Gy\(^{-1}\), –0.024, 2.38, and 3.8/(10\(^4\) PY Gy), respectively. The corresponding parameters for the rectum were 0.56, 0.033 Gy\(^{-1}\), –0.056, 6.9 and 0.73/(10\(^4\) PY Gy). The LAR estimates were expressed as the risk per 10000 people.

2.D Estimation of the average cancer risk

The average OED\(_{av}\) of bladder and rectum was found from the 3D-CRT and VMAT plans of all patients. The calculated OED\(_{av}\) was employed to estimate the respective average lifetime risk (LAR\(_{av}\)) for the appearance of radiotherapy-induced bladder and rectal malignancies using the equations of the previous subsection. The LAR\(_{av}\) was estimated for a typical 50-year-old patient at the time of irradiation and an attained age of 80 yrs. The LAR\(_{av}\) was combined with the baseline risk (BR) to estimate the average relative risk (RR\(_{av}\)) of carcinogenesis as follows:

\[
RR_{av} = (LAR_{av} + BR) / BR \tag{5}
\]

Based on SEER data, the BR of a 50-year-old healthy female to be diagnosed with bladder and rectal malignancies in 30 yrs is 0.68\% and 2.33\%, respectively.

2.E Statistics

The patient-specific second cancer risk estimates related to 3D-CRT for cervical carcinoma were compared with the assessments derived.
from the VMAT plans by using a Wilcoxon signed-rank test. Differences at the level of \( P \)-value of 0.05 or less were considered as significant. The Bland-Altman statistical test was also applied to determine the percentage mean difference (MD) between the organ-specific cancer risks estimated by the two treatment delivery techniques. The 95% confidence intervals between the risks derived from the two techniques were set to MD±1.96 SD, where SD is the standard deviation of the differences. Statistical analysis was performed using the GraphPad Prism software (Graph Pad Software Inc., CA, USA).

3 | RESULTS

3.A | Patient-specific cancer risk estimates

The OED calculations are presented in Figs. 2 and 3. The OED range of the bladder from 3D-CRT and VMAT was 17.1–18.1 cGy and 18.3–20.1 cGy, respectively (Fig. 2). The corresponding range for rectum was 831.0–980.7 cGy and 813.9–977.9 cGy (Fig. 3). The lifetime risks for the development of radiotherapy-induced malignancies are presented in Table 2. The LAR range for bladder cancer induction associated with 3D-CRT and VMAT for cervical cancer was found to be \( 2.3 \times 10^{-4} \) to \( 13.2 \times 10^{-4} \) and \( 2.5 \times 10^{-4} \) to \( 13.7 \times 10^{-4} \), respectively. The corresponding LARs for rectal malignancies were \( 10.3 \times 10^{-4} \) to \( 82.8 \times 10^{-4} \) and \( 9.9 \times 10^{-4} \) to \( 78.3 \times 10^{-4} \).

**Table 2** Lifetime attributable risk (LAR) estimates per 10000 people for the development of second bladder and rectal malignancies derived from 3D-CRT and VMAT plans of patients with cervical cancer.

| Patient | LAR for bladder cancer \((\times 10^{-4})\) | LAR for rectal cancer \((\times 10^{-4})\) |
|---------|---------------------------------|-------------------------------|
| 1       | 4.1    | 4.2         | 20.3 | 19.6 |
| 2       | 11.8   | 12.2        | 63.7 | 63.9 |
| 3       | 6.3    | 7.1         | 27.9 | 27.1 |
| 4       | 12.6   | 13.0        | 69.3 | 69.9 |
| 5       | 2.3    | 2.5         | 10.3 | 9.9  |
| 6       | 2.6    | 2.8         | 11.4 | 11.3 |
| 7       | 13.2   | 13.7        | 82.8 | 78.3 |
| 8       | 10.6   | 12.1        | 63.5 | 59.9 |
| 9       | 3.9    | 4.1         | 17.5 | 17.1 |
| 10      | 9.4    | 10.0        | 49.4 | 50.3 |
| 11      | 4.2    | 4.3         | 19.4 | 18.7 |
| 12      | 7.1    | 7.7         | 33.8 | 33.2 |
| 13      | 10.5   | 11.1        | 56.6 | 55.6 |
| 14      | 8.3    | 8.7         | 45.2 | 45.1 |
| 15      | 8.7    | 9.8         | 49.4 | 49.3 |
| 16      | 4.9    | 5.2         | 23.0 | 22.4 |
| 17      | 9.0    | 9.8         | 49.2 | 47.7 |
The LARs for second cancer induction from 3D-CRT were significantly different from those related to VMAT for cervical cancer (Bladder: \( P = 0.0003 \); Rectum: \( P = 0.0144 \)). The use of 3D-CRT resulted in lower bladder cancer risks than VMAT for all patients examined (Table 2). Conventional treatment led to an increased rectal cancer risk compared to that from VMAT in 14 of 17 study participants (Table 2). The Bland-Altman scatter plots are shown in Fig. 4. The MD between the bladder cancer risk estimates associated with 3D-CRT and VMAT was \(-6.6 \pm 3.4\%\) with 95% confidence intervals of 0.1% to \(-13.3\%\). The corresponding MD in the assessment of the probability for rectal cancer development was \(2.0 \pm 2.1\%\). The 95% limits of agreement were equal to \(-2.1\%\) and \(6.1\%\).

### 3.B Average cancer risk estimates

The \(\text{OED}_{av}\) of bladder attributable to 3D-CRT and VMAT for cervical carcinoma was 17.7 and 18.9 cGy, respectively. The corresponding quantity for the rectum was 909.2 and 890.4 cGy. The average risks are presented in Table 3. The LAR\(_{av}\) for the induction of second malignancies ranged from \(8.6 \times 10^{-4}\) to \(44.6 \times 10^{-4}\) by the organ of interest and the treatment delivery technique. The RR\(_{av}\) related to bladder and rectal cancer development was up to 1.135 and 1.191, respectively.

### 4 DISCUSSION

The unavoidable exposure of healthy tissues to ionizing radiation during external-beam radiotherapy of primary neoplasms may elevate the risk for subsequent carcinogenesis. The appearance of second tumors at distant sites from the primarily irradiated area is relatively rare. Dorr and Hermann\textsuperscript{29} found that almost 50% of the second tumors appear in the margin area of the treatment volume and less than 10% within the radiation fields. Welte et al.\textsuperscript{30} showed that 69% of the total number of second malignancies are presented at the field margins or inside the primarily irradiated region. The current study was focused on the assessment of the second cancer risk to the partially in-field bladder and rectum due to radiation therapy for uterine cervix carcinoma. These organs, which are characterized by the high susceptibility for radiation carcinogenesis, were partly exposed to primary radiation due to their adjacent location to the treatment volume.

The probabilities for the appearance of second malignancies were estimated for 3D-CRT with 10 MV photons and 6 MV VMAT of cervical carcinoma. The above photon energies are usually employed in our department for non-modulated and modulated treatment of primary pelvic tumors. The neutron contribution to the exposure of critical sites due to irradiation with 10 MV X-rays was considered as minimal.\textsuperscript{31} The second bladder and rectal cancer risks varied considerably by the patient’s age during treatment. Based on the risks shown in Table 2, the LAR for developing second bladder malignancies due to irradiation of a 40-year-old female (patient no. 7) was 5.5 times higher than that for patient no. 5 who was 68-year-old at the time of treatment. The corresponding ratio related to the second rectal cancer was about 8.0. The use of 3D-CRT resulted

### Table 3 Average lifetime attributable risk (LAR\(_{av}\)) and average relative risk (RR\(_{av}\)) for the development of second bladder and rectal malignancies following 3D-CRT and VMAT of a 50-year-old cervical cancer patient.

| Organ-at-risk | Technique | LAR\(_{av}\) (\(\times 10^{-4}\)) | RR\(_{av}\) |
|--------------|-----------|-------------------------------|---------|
| Bladder      | 3D-CRT    | 8.6                           | 1.126   |
|              | VMAT      | 9.2                           | 1.135   |
| Rectum       | 3D-CRT    | 44.6                          | 1.191   |
|              | VMAT      | 43.7                          | 1.187   |

![Fig. 4](image-url). Scatter plots presenting the differences between the patient-specific risks for developing bladder cancer (a), and rectal cancer (b) as estimated by the 3D-CRT and VMAT plans of patients with primary carcinoma of the uterine cervix against the average risk value. The dotted lines illustrate the 95% confidence intervals and the solid line is the mean% risk difference.
in significantly lower patient-specific LARs for bladder cancer induction than those from VMAT. The opposite result was found for the rectal cancer risk where VMAT significantly reduced this risk compared to 3D-CRT. Despite the above statistical significance, the differences between the second cancer risks estimated by the two treatment techniques were small for all patients. Bland-Altman analysis showed that the MD for the bladder and rectal cancer risk derived from pelvic VMAT and 3D-CRT is only 6.6% and 2.0%, respectively.

The RRav for developing a second malignancy to bladder or rectum after radiation therapy for cervical cancer was assessed for a typical 50-year-old female. The RRav for rectal cancer induction due to VMAT was 1.187. This result revealed that the application of the above treatment technique may elevate the lifetime rectal cancer risk by 18.7% in comparison to the probability of unirradiated 50-year-old females. The corresponding increase associated with the conventional 3D-CRT was 19.1%. The use of VMAT and 3D-CRT was also found to give an increased probability for developing bladder malignancies in respect to unirradiated people by 13.5% and 12.6%, respectively. The above baseline cancer risk increases are considerable and they cannot be ignored by physicians who follow-up the irradiated patients.

Limited data have been published about the theoretical risk of carcinogenesis to adjacent heavily exposed organs attributable to radiation therapy for cervical cancer.\(^\text{10,32}\) The cancer risk to the entire colon was estimated in these reports. Based on our results, the lifetime bladder cancer risks in females treated during the 5th decade of life with 3D-CRT were \(8.7 \times 10^{-4}\) to \(13.2 \times 10^{-4}\). These probabilities are similar to the lifetime risks of \((12–14) \times 10^{-4}\) for 40-year-old patients undergoing four-field box irradiation of gynecological carcinomas with 6 MV photons.\(^\text{32}\) Zwhalen et al.\(^\text{10}\) showed that the 6MV-IMRT leads to a bladder cancer risk increase of 11.4% compared to 3D-CRT when a linear-exponential model is used, whereas, the data analysis with a plateau model gave a decrease of 0.4%. Their results are comparable with the low differences presented in our study based on the application of a non-linear mechanistic model. We found that VMAT increases the probability for developing bladder malignancies in respect to 3D-CRT by 2.3%–13.2% in 95% of the irradiated patients.

The presented OEDs of bladder and rectum and the relevant cancer risks might contain uncertainties arising from the analysis of the DVHs derived from a commercial treatment planning software. Parts of the above organs-at-risk were located close but outside the treatment volume. Inaccuracies may exist in the out-of-field dose calculations generated by treatment planning systems.\(^\text{33}\) The results of this work may be also limited by errors in the definition of the organ-specific parameters of the mechanistic model applied for cancer risk estimation. The quantity \(\alpha/\beta\) was taken equal to 3 Gy for all tissues under investigation in accordance with the recommendation of Schneider et al.\(^\text{25}\) Reported experience has shown an insignificant change of the breast cancer risk with \(\alpha/\beta\) values from 1 to 5 Gy.\(^\text{24}\) It has to be mentioned that the estimated probabilities for radiation-induced bladder and rectal malignancies presented here solely referred to therapeutic doses. The use of image guidance procedures in clinical practice may result in small absorbed doses to these critical organs compared to those from radiation therapy.\(^\text{35}\) Further research is required to evaluate whether these imaging doses have an impact on the second cancer risk magnitude.

## 5 CONCLUSIONS

The use of VMAT for cervical cancer significantly reduced the probability for developing second rectal malignancies than 3D-CRT. The bladder cancer risk from VMAT was significantly high compared to that from the conventional irradiation. However, the absolute differences in the patient-specific probabilities for the appearance of second malignancies due to VMAT and 3D-CRT were found to be small. Both delivery techniques led to noticeable elevated second cancer risks compared to those for unirradiated population.

## ACKNOWLEDGEMENTS

This study was funded by the Research Committee of the University of Crete (Code: 10599).

## CONFLICT OF INTEREST

The authors declare that there is no conflict of interest regarding the publication of this article.

## DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## REFERENCES

1. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2020: a worldwide analysis. Lancet Glob Health. 2020;8:e191–203.
2. Howlader N, Noone AM, Krapcho M, et al, SEER Cancer Statistics Review, 1975–2017. Bethesda, MD: National Cancer Institute; 2020.
3. Viswanathan AN. Uterine cervix. In: Halperin EC, Wazer DE, Perez CA, Brady LW, eds. Perez & Brady’s Principles and Practice of Radiation Oncology, 7th edn. Philadelphia, PA: Wolters Kluver; 2019: 1651–1739.
4. Boice JD Jr, Day NE, Andersen A, et al, Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst 1985;74:955–975.
5. Kleinerman RA, Kosary C, Hildesheim A, et al, New malignancies following cancer of the cervix uteri, vagina, and vulva. In: Curtis RE, Freedman DM, Ron E, eds. New Malignancies among Cancer Survivors: SEER Cancer Registries, 1973–2000. Bethesda, MD: National Cancer Institute; 2006:207–230.
6. Chaturvedi AK, Engels EA, Gilbert ES, et al, Second cancers among 104760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst. 2007;99:1634–1643.
7. Cibula D, Poter R, Planchamp F, et al, The European Society of Gynaecological Oncology / European Society for Radiotherapy and Oncology / European Society of Pathology guidelines for the management of patients with cervical cancer. *Radiother Oncol*. 2018;127:404–416.
8. Klopp AH, Yeung AR, Deshmukh S, et al, Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology–RTOG 1203. *J Clin Oncol*. 2018;36:2538–2544.
9. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. *Int J Radiat Oncol Biol Phys*. 2003;56:83–88.
10. Zwahlen DR, Ruben JD, Jones P, Gagliardi F, Millar JL, Schneider U. Effect of intensity-modulated pelvic radiotherapy on second cancer risk in the postoperative treatment of endometrial and cervical cancer. *Int J Radiat Oncol Biol Phys*. 2009;74:539–545.
11. Cozzi L, Dinshaw KA, Shrivastava SK, et al, A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. *Radiother Oncol*. 2008;89:180–191.
12. Jia MX, Zhang XU, Yin CE, et al, Peripheral dose measurements in cervical cancer radiotherapy: a comparison of volumetric modulated arc therapy and step-and-shoot IMRT techniques. *Radiat Oncol*. 2014;9:61.
13. Bai W, Kou C, Yu W, et al, Dosimetric comparison of volumetric-modulated arc therapy and intensity-modulated radiation therapy in patients with cervical cancer: a meta-analysis. *Onco Targets Ther*. 2018;11:7179–7186.
14. Small W Jr, Mell LK, Anderson P, et al, Consensus guidelines for the delineation of the clinical target volume for intensity modulated pelvic radiotherapy in the postoperative treatment of endometrial and cervical cancer. *Int J Radiat Oncol Biol Phys*. 2008;71:428–434.
15. Wang Y, Chen L, Zhu F, Guo W, Zhang D, Sun W. A study of minimum segment width parameter on VMAT plan quality, delivery accuracy, and efficiency for cervical cancer using Monaco TPS. *J Appl Clin Med Phys*. 2018;19:e609–e615.
16. Chen A, Li Z, Chen L, Lin M, Li B, Chen F. The influence of increment of gantry on VMAT plan quality for cervical cancer. *J Radiat Res Appl Sci*. 2019;12:447–454.
17. Jhingran A, Winter K, Portelance L, et al, A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. *Int J Radiat Oncol Biol Phys*. 2012;84:e23–e28.
18. Howell RM, Scarboro SB, Taddei PJ, Krishnan S, Kry SF, Newhauser WD. Methodology for determining doses to in-field, out-of-field and partially in-field organs for late effects studies in photon radiotherapy. *Phys Med Biol*. 2010;55:7009–7023.
19. Hall EJ. Intensity-modulated radiation therapy, protons and the risk of second cancers. *Int J Radiat Oncol Biol Phys*. 2006;65:1–7.
20. Dasu A, Toma-Dasu I. Models for the risk of secondary cancers from radiation therapy. *Phys Med*. 2017;42:232–238.
21. Mazonakis M, Damilakis J. Cancer risk after radiotherapy for benign diseases. *Phys Med*. 2017;42:285–291.
22. Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. *Theor Biol Med Model*. 2011;8:27.
23. Murray LJ, Thompson CM, Lilley J, et al, Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy. *Phys Med Biol*. 2015;60:1237–1257.
24. Haciislamoglu E, Gungor G, Aydin G, et al, Estimation of secondary cancer risk after radiotherapy in high-risk prostate cancer patients with pelvic irradiation. *J Appl Clin Med Phys*. 2020;9:82–89.
25. Treutwein M, Loeschel R, Hipp M, Koelbl O, Dobler B. Secondary malignancy risk for patients with localized prostate cancer after intensity-modulated radiotherapy with and without flattening filter. *J Appl Clin Med Phys*. 2020;21:197–205.
26. Mazonakis M, Tzedakis A, Lyraraki E, Damilakis J. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas. *Med Phys*. 2016;43:1841–1848.
27. Arias E. United States life tables, 2017. *Natl Vital Stat Rep*. 2019;68:1–66.
28. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet*. 1986;327:307–310.
29. Dorr W, Hermann T. Second primary tumors after radiotherapy for malignancies. Treatment-related parameters. *Strahlenther Onkol*. 2002;177:357–362.
30. Welte B, Suhr P, Bottke D, et al, Second malignancies in high-dose fields of previous tumor radiotherapy. *Strahlenther Onkol*. 2010;186:174–179.
31. Kry SF, Salehpour M, Followill DS, et al, Out-of-field photon and neutron dose equivalents from step-and-shoot intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys*. 2005;62:1204–1216.
32. Mazonakis M, Kachris S, Damilakis J. Second cancer risk from radiotherapy for common solid tumors diagnosed in reproductive-aged females. *Radiat Prot Dosimetry*. 2018;182:208–214.
33. Kry SF, Bednarz B, Howell RM, et al, AAPM TG 158: Measurement and calculation of doses outside the treated volume from external-beam radiation therapy. *Med Phys*. 2017;44:e429–e429.
34. Schneider U, Sumila M, Robotka J, Gruber G, Mack A, Besserer J. Dose-response relationships for breast cancer induction at radiotherapy dose. *Radiat Oncol*. 2011;6:67.
35. Ding GX, Alaei P, Curran B, et al, Image guidance dose delivered during radiotherapy: quantification, management, and reduction: report of the AAPM therapy physics committee task group 180. *Med Phys*. 2018;45:e84–e99.